Blood test to predict heart side effects from lung cancer radiation
Part of Cancer, Lungs & breathing clinical trials.
This study looks for biomarkers (biological signs) in your blood that may show if you are at risk for heart problems from radiation therapy for lung cancer. It may help doctors personalize treatment to reduce heart risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have non-small cell lung cancer, or your doctor thinks you might based on scans or tissue samples.
- Your tumor is in a specific part of the lung near the heart or on the left side below the heart.
- You are scheduled to receive a certain type of radiation therapy (hypofractionated radiation) with specific dose ranges.
- Your radiation treatment area is at or below the top of your heart.
- You are not receiving chemotherapy or immunotherapy during this treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how radiation therapy affects the heart in people being treated for lung, esophageal, or breast cancer. By watching the heart during and after treatment, researchers hope to find ways to lower heart side effects.
This study looks at how chest radiation treatment affects the heart and lungs in people with certain lung or esophagus cancers. It may help doctors better predict and prevent these side effects during curative (aimed at cure) radiotherapy.
This study looks at whether PET-CT scans can help detect heart damage caused by radiation therapy in patients with stage III lung cancer. If you're getting chemotherapy and radiation together, you may participate to help doctors find ways to reduce heart risks.
This trial tests whether a simple blood test (ctDNA) can help doctors decide if you need radiation therapy after lung cancer surgery. The goal is to tailor your treatment to your individual risk, possibly avoiding extra radiation if you don't need it.
This trial tests an early heart-focused intervention guided by a special heart recording (impedance cardiography) in people with locally advanced, unresectable stage III non-small cell lung cancer. The goal is to improve heart-related safety during planned radiation and chemotherapy, with or without immunotherapy.
This trial tests whether common heart medicines (statins or ACE-inhibitors) can protect the heart during cancer radiation therapy. It is for adults who are about to start chest radiation and have not taken these drugs before.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.